These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31371039)

  • 41. Psychiatrists' opinion towards medication discontinuation in remitted first-episode psychosis: A multi-site study of the Asian Network for Early Psychosis.
    Hui CL; Wong AK; Leung WW; Lee EH; Chan SK; Chang WC; Chen EY; Chan TC; Swapna V; Tagata H; Tsujino N; Nemoto T; Mizuno M; Kang NI; Kim SW; Chung YC
    Early Interv Psychiatry; 2019 Dec; 13(6):1329-1337. PubMed ID: 30485671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics.
    Hamann J; Mendel R; Cohen R; Heres S; Ziegler M; Bühner M; Kissling W
    Psychiatr Serv; 2009 Aug; 60(8):1107-12. PubMed ID: 19648199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attitudes of Croatian patients with severe mental illness towards long-acting injectable antipsychotics.
    Bjedov S; Ciglar M; Maleković H
    Psychiatr Danub; 2016 Sep; 28(3):278-283. PubMed ID: 27658837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.
    Sugawara N; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Suzuki Y; Someya T
    PLoS One; 2014; 9(1):e86826. PubMed ID: 24466260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.
    Alphs L; Nasrallah HA; Bossie CA; Fu DJ; Gopal S; Hough D; Turkoz I
    Int Clin Psychopharmacol; 2016 Jul; 31(4):202-9. PubMed ID: 26974214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring predictors of medication adherence among inpatients with schizophrenia in Singapore's mental health settings: A non-experimental study.
    Tham XC; Xie H; Chng CML; Seah XY; Lopez V; Klainin-Yobas P
    Arch Psychiatr Nurs; 2018 Aug; 32(4):536-548. PubMed ID: 30029745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy.
    James BO; Omoaregba JO; Raji SO; Imishue OE; Okonoda KM; Nyamali YI; Famuyiwa PA; Correll CU
    Psychiatry Res; 2017 Feb; 248():134-139. PubMed ID: 28063386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
    Cañas F; Möller HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia.
    Sweileh WM; Ihbesheh MS; Jarar IS; Sawalha AF; Abu Taha AS; Zyoud SH; Morisky DE
    Curr Clin Pharmacol; 2012 Feb; 7(1):49-55. PubMed ID: 22299769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validity of the 24-h medication use recall for assessing medication adherence among psychiatric outpatients.
    Adelufosi AO; Ogunwale A
    Asian J Psychiatr; 2013 Feb; 6(1):85. PubMed ID: 23380328
    [No Abstract]   [Full Text] [Related]  

  • 54. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicians' attitudes toward the use of long-acting injectable antipsychotics.
    Samalin L; Charpeaud T; Blanc O; Heres S; Llorca PM
    J Nerv Ment Dis; 2013 Jul; 201(7):553-9. PubMed ID: 23817151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia.
    Samalin L; de Chazeron I; Blanc O; Brunel L; Fond G; Llorca PM
    Schizophr Res; 2016 Dec; 178(1-3):1-5. PubMed ID: 27637362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey.
    Olivares JM; Thirunavukarasu M; Kulkarni J; Zhang HY; Zhang M; Zhang F
    Neuropsychiatr Dis Treat; 2013; 9():1163-70. PubMed ID: 23976858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.